Clinical Report: Link Between KCNJ11 E23K Polymorphism and Diabetic Retinopathy
Overview
This study investigates the association between the KCNJ11 E23K polymorphism and the severity of diabetic retinopathy (DR) in Lebanese individuals with type 2 diabetes (T2DM). The findings indicate a stage-specific relationship, particularly with proliferative diabetic retinopathy (PDR).
Background
Diabetic retinopathy is a significant microvascular complication of diabetes and a leading cause of visual impairment. Understanding genetic factors that contribute to the severity of DR can enhance risk stratification and management strategies. The KCNJ11 gene, which encodes a key component of the ATP-sensitive potassium channel, has been implicated in T2DM and may influence the progression of retinopathy.
Data Highlights
Group
Sample Size
Findings
Diabetes Without Retinopathy (DWR)
933
Reference group
Non-Proliferative DR (NPDR)
342
Compared to DWR
Proliferative DR (PDR)
140
Increased odds with K allele
Normoglycemic Controls
1389
Comparison group
Key Findings
The K allele of KCNJ11 E23K was more frequent in T2DM patients compared to normoglycemic controls.
No overall association was found between E23K and diabetic retinopathy, but a stage-specific effect was observed.
Each additional K allele increased the odds of PDR compared to DWR.
K/K homozygosity was associated with a stronger recessive effect on PDR risk.
The K/K genotype was enriched among DR patients with HbA1c ≤ 7.0%, indicating risk under good glycemic control.
Risk associations were more pronounced in individuals with diabetes duration ≥10 years.
Clinical Implications
The findings indicate that KCNJ11 E23K may be associated with the risk of advanced diabetic retinopathy, particularly PDR.
Conclusion
The KCNJ11 E23K polymorphism demonstrates a specific association with proliferative diabetic retinopathy in a Lebanese cohort.
Analysis of more than 61,000 patients found higher odds of elevated loneliness scores among those reporting blindness and those with diabetic retinopathy, but not among patients with glaucoma or age-related macular degeneration.
